Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcoming investor conferences:
BofA Securities 2022 Healthcare Conference
Date: Friday, May 13, 2022
Virtual 1x1 meetings only
H.C. Wainwright Global Investment Conference
Presentation date: Tuesday, May 24, 2022
Pre-recorded on-demand presentation available beginning at 7:00 AM ET
The on-demand webcast of the presentation at the H.C. Wainwright Global Investment Conference be available on the Company's website at www.vorbio.com. An archived replay of the webcast will also be available.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.33 |
| Daily Change: | -0.03 -2.21 |
| Daily Volume: | 359,472 |
| Market Cap: | US$165.640M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
